[HTML][HTML] Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
…, M Sznol, DF McDermott, HM Kluger… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T
cells that downmodulates effector functions and limits the generation of immune memory. PD-…
cells that downmodulates effector functions and limits the generation of immune memory. PD-…
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
…, EC Holman, M Bosenberg, M Sznol, HM Kluger… - Nature …, 2012 - nature.com
We characterized the mutational landscape of melanoma, the form of skin cancer with the
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …
[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
…, SP Fling, PA Friedlander, HM Kluger… - … England Journal of …, 2016 - Mass Medical Soc
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 …
…, H Gerrish, X Yao, V Chiang, HM Kluger - The lancet …, 2016 - thelancet.com
Background Immunotherapy targeting the PD-1 axis has activity in several tumour types. We
aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients …
aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients …
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 …
Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-…
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of PD-…
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
Affymetrix and spotted oligonucleotide microarrays were used to assess global differential
gene expression comparing normal human melanocytes with six independent melanoma cell …
gene expression comparing normal human melanocytes with six independent melanoma cell …
High HSP90 expression is associated with decreased survival in breast cancer
The heat shock protein HSP90 chaperones proteins implicated in breast cancer progression,
including Her2/neu. HSP90-targeting agents are in clinical trials for breast cancer. HSP90 …
including Her2/neu. HSP90-targeting agents are in clinical trials for breast cancer. HSP90 …
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
…, LB Jilaveanu, W Damsky, M Sznol, HM Kluger… - Nature, 2021 - nature.com
Tumours use various strategies to evade immune surveillance 1 , 2 . Immunotherapies
targeting tumour immune evasion such as immune checkpoint blockade have shown …
targeting tumour immune evasion such as immune checkpoint blockade have shown …
[HTML][HTML] Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
…, I Puzanov, FS Hodi, HM Kluger… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Blockade of the programmed death-1 inhibitory cell-surface molecule on immune
cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor …
cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor …
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
We report on whole-exome sequencing (WES) of 213 melanomas. Our analysis established
NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in …
NF1, encoding a negative regulator of RAS, as the third most frequently mutated gene in …